Загрузка...

FDA accepted the resubmitted NDA for reproxalap

Big update in eye care! 👁️
Aldeyra Therapeutics’ new drug candidate Reproxalap is officially under FDA review for treating dry eye disease.

🧪 In a new clinical trial, Reproxalap successfully reduced eye discomfort — a key symptom that bothers most patients during flare-ups.

⚠️ This video contains AI-generated voiceover for informational purposes. No real individuals are speaking.

Видео FDA accepted the resubmitted NDA for reproxalap канала ClinOrbit
#Reproxalap #DryEyeDisease #FDAReview #DrugApproval #ClinicalTrials #NewDrugApplication #EyeTreatment #OcularHealth #Ophthalmology #AldeyraTherapeutics #HealthNews #MedicalUpdate #PharmaNews #BiotechNews #MedTech #DrugDevelopment #ClinOrbit #YouTubeShorts #ShortsUpdate #QuickMedNews #ScienceIn60Seconds
Комментарии отсутствуют
Информация о видео
17 июля 2025 г. 19:06:56
00:00:41
ClinOrbit
Теги
Правообладателям
Жалоба на материал Недопустимый материал Нарушение авторских прав
Комментарии
Поделиться
Другие видео канала

FDA Clears IND for New Bispecific Antibody AXN 2510 for Solid Tumors!FDA Clears IND for New Bispecific Antibody AXN 2510 for Solid Tumors!

FDA approved ANZUPGO® delgocitinib cream 20 mgg for moderate to severe chronic hand eczema CHEFDA approved ANZUPGO® delgocitinib cream 20 mgg for moderate to severe chronic hand eczema CHE

FDA has accepted and granted Priority Review for tabelecleucelFDA has accepted and granted Priority Review for tabelecleucel

BREAKING in Cancer Research- Orphan Drug Designation for BP2202BREAKING in Cancer Research- Orphan Drug Designation for BP2202

FDA Approves EKTERLY® (sebetralstat)-First Oral On-Demand Treatment for Hereditary Angioedema!FDA Approves EKTERLY® (sebetralstat)-First Oral On-Demand Treatment for Hereditary Angioedema!

New Hope for Lung Cancer: China Approves ORPATHYS & TAGRISSO ComboNew Hope for Lung Cancer: China Approves ORPATHYS & TAGRISSO Combo

Deramiocel BLA Update: Capricor & FDADeramiocel BLA Update: Capricor & FDA

FDA Approves SIR-Spheres® Y-90 for Liver Cancer!FDA Approves SIR-Spheres® Y-90 for Liver Cancer!

sNDA for toripalimab + disitamab vedotin as 1L HER2 expressing urothelial carcinomasNDA for toripalimab + disitamab vedotin as 1L HER2 expressing urothelial carcinoma

Corcept Files NDA for Ovarian Cancer Drug Relacorilant!Corcept Files NDA for Ovarian Cancer Drug Relacorilant!

PAH Breakthrough: Winrevair Gets FDA Priority ReviewPAH Breakthrough: Winrevair Gets FDA Priority Review

Orphan Drug Status to a potential breakthrough treatment — SPG601 from Spinogenix!Orphan Drug Status to a potential breakthrough treatment — SPG601 from Spinogenix!

sNDA submitted to U S FDA for CAPLYTA® lumateperonesNDA submitted to U S FDA for CAPLYTA® lumateperone

Big leap in kidney disease treatment!IND for PS-002 approved by FDA for IgANBig leap in kidney disease treatment!IND for PS-002 approved by FDA for IgAN

FDA granted Orphan Drug Designation to Mustang Bio’s MB-101 to Treat Astrocytomas and GlioblastomaFDA granted Orphan Drug Designation to Mustang Bio’s MB-101 to Treat Astrocytomas and Glioblastoma

ENHERTU plus pertuzumab: Granted Breakthrough Therapy Designation by the U.S. FDA!ENHERTU plus pertuzumab: Granted Breakthrough Therapy Designation by the U.S. FDA!

U S FDA approved an expanded indication for AJOVY® fremanezumab vfrm for episodic migraineU S FDA approved an expanded indication for AJOVY® fremanezumab vfrm for episodic migraine

Swissmedic has approved IFINWIL® for paediatric patients with high-risk neuroblastomaSwissmedic has approved IFINWIL® for paediatric patients with high-risk neuroblastoma

IXCHIQ® Cleared for Elderly Use in EU!IXCHIQ® Cleared for Elderly Use in EU!

U S FDA granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® zongertinibU S FDA granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® zongertinib

European Commission Approved TEVIMBRA tislelizumab for Nasopharyngeal CarcinomaEuropean Commission Approved TEVIMBRA tislelizumab for Nasopharyngeal Carcinoma

Яндекс.Метрика
© 2008-2025 «Информационно-развлекательный портал города Верхняя Салда»
| Карта портала | Контакты | Сообщить об ошибке | Соглашения Пользовательское соглашение Соглашение о конфиденциальности Согласие на обработку персональных данных Информация для правообладателей Об использовании Cookies
salda_ws salda.ws@mail.ru
Сейчас на сайте: 407 Статистика портала
Все заметки Новая заметка Страницу в заметки
Страницу в закладки Мои закладки
На информационно-развлекательном портале SALDA.WS применяются cookie-файлы. Нажимая кнопку Принять, вы подтверждаете свое согласие на их использование.
О CookiesНапомнить позжеПринять